MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.57
+0.09
+0.86%
After Hours: 10.75 +0.18 +1.70% 19:58 01/15 EST
OPEN
10.38
PREV CLOSE
10.48
HIGH
10.99
LOW
9.98
VOLUME
2.30M
TURNOVER
--
52 WEEK HIGH
12.99
52 WEEK LOW
1.630
MARKET CAP
369.46M
P/E (TTM)
-45.2483
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
FCEL, GME, MAXR and FCAU among midday movers
Gainers: Datasea (DTSS) +90%.Lexicon Pharmaceuticals (LXRX) +85%.Pennsylvania Real Estate Investment Trust (PEI) +50%.DPW Holdings (DPW) +36%.Organogenesis (ORGO) +34%.Acacia Communications (ACIA) +33%.Bicycle Therapeutics (BCYC) +31%.AeroVironment (AVAV) +29%.Maxar Technologies (MAXR) +27%.GameStop (GME) +25%.Losers: Viveve Medical (VIVE) -21%.Volt Information
Seekingalpha · 3d ago
Lexicon Pharmaceuticals and NantKwest among healthcare gainers; Cassava Sciences among losers
Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx
Seekingalpha · 3d ago
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)
Benzinga · 3d ago
Cassava Sciences Appoints Dr. James Kupiec As Chief Clinical Development Officer
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer AUSTIN, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) a clinical-stage biotechnology company focused on
Benzinga · 01/04 13:31
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company’s Phase 3 development of simufilam for Alzheimer’s disease.AUSTIN, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (N...
GlobeNewswire · 01/04 13:30
Cassava Sciences' (SAVA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Cassava Sciences (SAVA).
Zacks · 12/22/2020 12:31
Is SAVA A Good Stock To Buy Now?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Insider Monkey · 12/08/2020 01:19
Is SAVA A Good Stock To Buy Now?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under manageme...
Insider Monkey · 12/08/2020 01:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAVA. Analyze the recent business situations of Cassava Sciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAVA stock price target is 19.33 with a high estimate of 24.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 8.60M
% Owned: 24.60%
Shares Outstanding: 34.95M
TypeInstitutionsShares
Increased
19
554.21K
New
26
1.04M
Decreased
15
776.47K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Director/President/Chief Executive Officer
Remi Barbier
Chief Financial Officer
Eric Schoen
Chief Operating Officer/Director
Nadav Friedmann
Other
James Kupiec
Independent Director
Robert Gussin
Independent Director
Michael O' Donnell
Independent Director
Sanford Robertson
Independent Director
Patrick Scannon
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/07/2012
Dividend USD 0.75
12/13/2012
10/25/2010
Dividend USD 2
12/13/2010
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SAVA
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cassava Sciences Inc stock information, including NASDAQ:SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.